Figure 4.

Mass cytometry data from a validation cohort of 31 pediatric cancer (PC) patients and 24 pediatric healthy (PH) donors confirms the NK cell alterations identified in pediatric cancer patients

(A) Frequencies of the main immune cell subsets shown at the level of each individual for both pediatric healthy and pediatric cancer patients.

(B) Gating strategy for the three NK subsets in pediatric healthy and pediatric cancer patients.

(C) Frequency of each NK subset shown for individual for pediatric healthy donors and pediatric cancer patients.

(D) Mass cytometry analysis of pediatric cancer patients and pediatric healthy donors showing percentage of total NK cells positive for the indicated markers. The error bars show the mean +/− one standard deviation. p values were calculated using Wilcoxon ranked sum tests with false discovery rate at 5% and correction using the Benjamini-Hochberg method. Significant results are indicated: ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.